Empreses emergents
2011
ZYRNAT BIOTHERAPEUTICS SLL'empresa va cessar l'activitat de petits ARN inhibidors (siRNAs) i microRNAs (mRNAs) dissenyats a mida i validats in vitro i in vivo.
Adreça
Carrer de la Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Espanya
Propietat CERCA
L'Hospitalet de Llobregat, Spain
2004
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)
Contacte del Centre CERCA
LT
Laia TravesetResponsable innovació
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)Altres accionistes públics catalans
Logotip
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
Zyrnat Biotherapeutics’ technology focus is on the post-translational silencing of biological targets known to be, or suspected of being associated with disease states.
Zyrnat Biotherapeutic’s expertise in designing, formulating and validating silencing-RNA oligo-nucleotides allows its clients to test biomedical research hypotheses in a highly reliable and expedited manner.
Our leadership team is available to discuss your project in detail and offer you a tailored approach
Zyrnat Biotherapeutic’s expertise in designing, formulating and validating silencing-RNA oligo-nucleotides allows its clients to test biomedical research hypotheses in a highly reliable and expedited manner.
Our leadership team is available to discuss your project in detail and offer you a tailored approach
Descripció del producte
We offer in vitro and in vivo validated, custom-designed small-inhibitory-RNAs (siRNAs) and micro-RNAs (mRNAs) to biomedical research groups as well as biotechnology and pharmaceutical company clients.Biotechnology products, such as highly specific monoclonal antibodies and fusion protein complexes, have has been successfully used against extracellular biological targets. Intracellular proteins, however, cannot be currently targeted through this approach due to the inability of large molecular proteins to enter and survive the intracellular environment.
Silencing-RNA technology provides a universal approach to specifically modulate target protein expression regardless of location.
Silencing-RNA technology provides a universal approach to specifically modulate target protein expression regardless of location.
Empresa tancada o sortida